Follow the LifeMD, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, LifeMD, Inc. has recorded 6 reports. Market capitalisation: €224.4m. The latest transaction was reported on 1 April 2026 (Attribution). Among the most active insiders: Schreiber Justin. All data is free.
Analysts rate LifeMD, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$9.88.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
6 of 6 declarations
LifeMD, Inc. is a U.S.-based digital health and telehealth company listed on the NASDAQ in the United States. It operates a direct-to-patient care model built around a proprietary technology platform, an affiliated medical group available across all 50 states, and a nationwide mail-order pharmacy network. For French-speaking investors, LifeMD fits squarely into the digital healthcare theme: a sector where growth depends on user adoption, recurring patient engagement, operational discipline, and the ability to turn virtual care into a scalable, monetizable service model. The company was originally formed in Delaware in the 1990s under a prior corporate identity and later evolved into a consumer-oriented telehealth platform. Its current management team has emphasized building LifeMD into a leading virtual care brand in America and beyond. Corporate disclosures and investor materials point to New York as the company’s principal business address, while the patient care structure relies on state-by-state affiliated professional corporations, including administrative leadership from Florida. In practice, LifeMD’s footprint is national rather than regional, which is important for a telehealth operator seeking scale in a fragmented healthcare market. LifeMD’s business is organized around several complementary service lines. The core offering is virtual primary care and urgent care, delivered through same-day video visits or message-based consultations when appropriate. Beyond general telehealth, the company has expanded into specialized programs for weight management, men’s and women’s health, allergy and asthma, dermatology, and mental health. This broader portfolio is strategically relevant because it increases the number of recurring touchpoints with patients and supports cross-selling across multiple clinical needs. LifeMD also highlights access to lab testing and prescription fulfillment through its pharmacy network, which improves convenience and deepens the end-to-end care experience. From a competitive standpoint, LifeMD operates in a crowded market that includes telehealth platforms, virtual primary care providers, and specialty digital health companies. Its competitive edge comes from combining national coverage, a broad care menu, and an integrated care pathway that links consultations, diagnostics, and prescriptions. That said, the business is still exposed to the usual pressures of digital health: customer acquisition costs, reimbursement dynamics, clinical compliance, and the challenge of sustaining patient retention over time. Recent developments show continued emphasis on growth in core virtual care categories. The company has been promoting same-day access, expanded mental health offerings, and weight-management programs that can include GLP-1 medications when clinically appropriate. LifeMD has also continued to position its platform around convenience, affordability, and longitudinal care, which are central themes in the U.S. telehealth market. For investors, the name remains a growth-oriented healthcare technology story with nationwide reach, but one that must prove its ability to scale profitably and defend its position in a highly competitive, regulation-sensitive industry.